LONDON (Alliance News) - Drugmaker AstraZeneca PLC on Monday said its Tagrisso lung cancer treatment met its primary endpoint in phase 3 trials.
AstraZeneca said the drug demonstrated superior progression-free survival rates in comparison to standard platinum-based doublet chemotherapy.
The group added the objective response rate, disease control rate and duration of response also achieved clinically-meaningful improvement against standard chemotherapy.
"The AURA3 results demonstrate the benefits of our science-led approach that enabled the rapid development of Tagrisso as a targeted treatment to address the most common cause of resistance to a first-generation EGFR-TKI for patients with metastatic EGFR-mutant lung cancer. We remain committed to exploring the potential of Tagrisso to further extend its reach and help meet patient need," said Sean Bohen, executive vice-president for global medicines development and chief medical officer at AstraZeneca.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Astrazeneca (AZN)